IIDR Supports Preclinical Drug Discovery Through New Funding Initiative
The Michael G. DeGroote Institute for Infectious Disease Research’s Centre for Microbial Chemical Biology (CMCB) is a unique facility with state-of-the-art infrastructure and experienced staff to support preclinical drug discovery and molecular biology.
In an effort to capitalize on this infrastructure, the IIDR recently launched a new funding initiative to support novel, collaborative research between the Institute’s investigators and CMCB staff.
Through this initiative, IIDR investigators – whose research activities involve high-throughput drug screening – will have the opportunity to develop an assay suitable for high throughput screening (HTS) and perform a pilot screen using a subset of the McMaster compound collections.
Awardees of the inaugural IIDR High Throughput Screening Project Fund have been identified, and the IIDR would like to congratulate Dr. Eric Brown, Dr. Lori Burrows, Dr. Ryan Lamers and Dr. Karen Mossman.
NewsRelated News
News Listing
Brighter World ➚
Researchers invent artificial intelligence model to design new superbug-fighting antibiotics
News
March 23, 2024
FHS News ➚
Decades of McMaster tuberculosis research leading to new prevention and control strategies
News
March 22, 2024